

## S 3390

CCM–CARE Act of 2021

**Congress:** 117 (2021–2023, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Dec 14, 2021

**Current Status:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

**Latest Action:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Dec 14, 2021)

**Official Text:** <https://www.congress.gov/bill/117th-congress/senate-bill/3390>

### Sponsor

**Name:** Sen. Lujan, Ben Ray [D-NM]

**Party:** Democratic • **State:** NM • **Chamber:** Senate

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Heinrich, Martin [D-NM]	D · NM		Dec 14, 2021

### Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Dec 14, 2021

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

No related bills are listed.

## **Cerebral Cavernous Malformations Clinical Awareness, Research, and Education Act of 2021 or the CCM-CARE Act of 2021**

This bill requires the National Institutes of Health (NIH) and other agencies to expand and coordinate their efforts to research cerebral cavernous malformation. (Cerebral cavernous malformation is a condition in which blood vessels in the brain and spinal cord become enlarged, which can lead to seizures, paralysis, hearing or vision loss, and bleeding in the brain.)

The NIH must (1) award grants for medical, clinical, and pharmacological research; (2) award grants to support a network of clinical research centers intended to develop a cure for the condition; and (3) convene a Cerebral Cavernous Malformations Research Consortium to develop programs for clinicians, scientists, and patients.

The Centers for Disease Control and Prevention must award grants to research entities for collecting and reporting data about cerebral cavernous malformation.

The Food and Drug Administration must accelerate the clinical trial process for cerebral cavernous malformation by supporting (1) appropriate laboratory indicators of the condition, (2) the qualification of clinical outcome measures related to quality of life, (3) investigational drug applications, and (4) expedited peer-review pathways.

### **Actions Timeline**

---

- **Dec 14, 2021:** Introduced in Senate
- **Dec 14, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.